Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019.
Plasmodium falciparum
Artemether-Lumefantrine
Malaria
Therapeutic efficacy
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
09 Apr 2024
09 Apr 2024
Historique:
received:
21
12
2023
accepted:
04
04
2024
medline:
10
4
2024
pubmed:
10
4
2024
entrez:
9
4
2024
Statut:
epublish
Résumé
Artemisinin-based combination therapy (ACT) has been a major contributor to the substantial reductions in global malaria morbidity and mortality over the last decade. In Tanzania, artemether-lumefantrine (AL) was introduced as the first-line treatment for uncomplicated Plasmodium falciparum malaria in 2006. The World Health Organization (WHO) recommends regular assessment and monitoring of the efficacy of the first-line treatment, specifically considering that artemisinin resistance has been confirmed in the Greater Mekong sub-region. This study's main aim was to assess the efficacy and safety of AL for treating uncomplicated P. falciparum malaria in Tanzania. This was a single-arm prospective antimalarial drug efficacy trial conducted in four of the eight National Malaria Control Programme (NMCP) sentinel sites in 2019. The trial was carried out in outpatient health facilities in Karume-Mwanza region, Ipinda-Mbeya region, Simbo-Tabora region, and Nagaga-Mtwara region. Children aged six months to 10 years with microscopy confirmed uncomplicated P. falciparum malaria who met the inclusion criteria were recruited based on the WHO protocol. The children received AL (a 6-dose regimen of AL twice daily for three days). Clinical and parasitological parameters were monitored during follow-up over 28 days to evaluate drug efficacy. A total of 628 children were screened for uncomplicated malaria, and 349 (55.6%) were enrolled between May and September 2019. Of the enrolled children, 343 (98.3%) completed the 28-day follow-up or attained the treatment outcomes. There were no early treatment failures; recurrent infections during follow-up were common at two sites (Karume 29.5%; Simbo 18.2%). PCR-corrected adequate clinical and parasitological response (ACPR) by survival analysis to AL on day 28 of follow-up varied from 97.7% at Karume to 100% at Ipinda and Nagaga sites. The commonly reported adverse events were cough, skin pallor, and abdominal pain. The drug was well tolerated, and no serious adverse event was reported. This study showed that AL had adequate efficacy and safety for the treatment of uncomplicated falciparum malaria in Tanzania in 2019. The high recurrent infections were mainly due to new infections, highlighting the potential role of introducing alternative artemisinin-based combinations that offer improved post-treatment prophylaxis, such as artesunate-amodiaquine (ASAQ).
Sections du résumé
BACKGROUND
BACKGROUND
Artemisinin-based combination therapy (ACT) has been a major contributor to the substantial reductions in global malaria morbidity and mortality over the last decade. In Tanzania, artemether-lumefantrine (AL) was introduced as the first-line treatment for uncomplicated Plasmodium falciparum malaria in 2006. The World Health Organization (WHO) recommends regular assessment and monitoring of the efficacy of the first-line treatment, specifically considering that artemisinin resistance has been confirmed in the Greater Mekong sub-region. This study's main aim was to assess the efficacy and safety of AL for treating uncomplicated P. falciparum malaria in Tanzania.
METHODS
METHODS
This was a single-arm prospective antimalarial drug efficacy trial conducted in four of the eight National Malaria Control Programme (NMCP) sentinel sites in 2019. The trial was carried out in outpatient health facilities in Karume-Mwanza region, Ipinda-Mbeya region, Simbo-Tabora region, and Nagaga-Mtwara region. Children aged six months to 10 years with microscopy confirmed uncomplicated P. falciparum malaria who met the inclusion criteria were recruited based on the WHO protocol. The children received AL (a 6-dose regimen of AL twice daily for three days). Clinical and parasitological parameters were monitored during follow-up over 28 days to evaluate drug efficacy.
RESULTS
RESULTS
A total of 628 children were screened for uncomplicated malaria, and 349 (55.6%) were enrolled between May and September 2019. Of the enrolled children, 343 (98.3%) completed the 28-day follow-up or attained the treatment outcomes. There were no early treatment failures; recurrent infections during follow-up were common at two sites (Karume 29.5%; Simbo 18.2%). PCR-corrected adequate clinical and parasitological response (ACPR) by survival analysis to AL on day 28 of follow-up varied from 97.7% at Karume to 100% at Ipinda and Nagaga sites. The commonly reported adverse events were cough, skin pallor, and abdominal pain. The drug was well tolerated, and no serious adverse event was reported.
CONCLUSION
CONCLUSIONS
This study showed that AL had adequate efficacy and safety for the treatment of uncomplicated falciparum malaria in Tanzania in 2019. The high recurrent infections were mainly due to new infections, highlighting the potential role of introducing alternative artemisinin-based combinations that offer improved post-treatment prophylaxis, such as artesunate-amodiaquine (ASAQ).
Identifiants
pubmed: 38594679
doi: 10.1186/s12936-024-04931-0
pii: 10.1186/s12936-024-04931-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101Informations de copyright
© 2024. The Author(s).
Références
WHO. World malaria report 2019. Geneva, World Health Organization, 2019. https://iris.who.int/handle/10665/330011 .
WHO. Guidelines for malaria. Geneva, World Health Organization, 2021. https://iris.who.int/handle/10665/339609 . WHO/UCN/GMP/2021.012021.
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.
doi: 10.1056/NEJMoa1314981
pubmed: 25075834
pmcid: 4143591
Boni MF, White NJ, Baird JK. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLoS Med. 2016;13: e1001984.
doi: 10.1371/journal.pmed.1001984
pubmed: 27022739
pmcid: 4811558
Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar J. 2018;17:369.
doi: 10.1186/s12936-018-2524-x
pubmed: 30333022
pmcid: 6192314
Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malar J. 2016;15:316.
doi: 10.1186/s12936-016-1341-3
pubmed: 27287612
pmcid: 4901409
Mårtensson A, Strömberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar. Tanzania Clin Infect Dis. 2005;41:1079–86.
doi: 10.1086/444460
pubmed: 16163624
Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005;191:1014–7.
doi: 10.1086/427997
pubmed: 15717281
Mwaiswelo R, Ngasala B, Jovel I, Xu W, Larsson E, Malmberg M, et al. Prevalence of and risk factors associated with polymerase chain reaction-determined Plasmodium falciparum positivity on Day 3 after initiation of artemether–lumefantrine treatment for uncomplicated malaria in Bagamoyo District, Tanzania. Am J Trop Med Hyg. 2019;100:1179–86.
doi: 10.4269/ajtmh.18-0729
pubmed: 30860013
pmcid: 6493965
Bretscher MT, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, et al. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Med. 2020;18:47.
doi: 10.1186/s12916-020-1494-3
pubmed: 32098634
pmcid: 7043031
Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district. Tanzania Malar J. 2013;12:103.
doi: 10.1186/1475-2875-12-103
pubmed: 23506218
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.
doi: 10.1056/NEJMoa0808859
pubmed: 19641202
pmcid: 3495232
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.
doi: 10.1038/nature12876
pubmed: 24352242
Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163–71.
doi: 10.1056/NEJMoa2101746
pubmed: 34551228
Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120–8.
doi: 10.1016/S1473-3099(21)00142-0
pubmed: 33864801
pmcid: 10202849
WHO. Strategy to respond to antimalarial drug resistance in Africa. Geneva, World Health Organization, 2022. https://iris.who.int/handle/10665/364531 .
Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, et al. Evidence of artemisinin partial resistance in North-western Tanzania: clinical and drug resistance markers study. medRxiv 2024.
WHO. Methods for surveillance of antimalarial drug efficacy. Geneva, World Health Organization, 2009. https://iris.who.int/handle/10665/44048 .
Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88.
doi: 10.1186/s12936-019-2730-1
pubmed: 30898164
pmcid: 6427902
Mandara CI, Kavishe RA, Gesase S, Mghamba J, Ngadaya E, Mmbuji P, et al. High efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Muheza and Kigoma Districts, Tanzania. Malar J. 2018;17:261.
doi: 10.1186/s12936-018-2409-z
pubmed: 29996849
pmcid: 6042436
East African Network for Monitoring Antimalarial Treatment. The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health. 2003;8:860–7.
doi: 10.1046/j.1360-2276.2003.01114.x
Tanzania Ministry of Health CD, Gender, Elderly and Children. National malaria strategic plan 2021–2025: transitioning to malaria elimination in phases. Tanzania, Dodoma, 2020.
Mwalimu CD, Kiware S, Nshama R, Derua Y, Machafuko P, Gitanya P, et al. Dynamics of malaria vector composition and Plasmodium falciparum infection in mainland Tanzania: 2017–2021 data from the national malaria vector entomological surveillance. Malar J. 2024;23:29.
doi: 10.1186/s12936-024-04849-7
pubmed: 38243220
pmcid: 10797900
Sinka ME, Bangs MJ, Manguin S, Coetzee M, Mbogo CM, Hemingway J, et al. The dominant Anopheles vectors of human malaria in Africa, Europe and the Middle East: occurrence data, distribution maps and bionomic précis. Parasit Vectors. 2010;3:117.
doi: 10.1186/1756-3305-3-117
pubmed: 21129198
pmcid: 3016360
Tanzania Ministry of Health and Social Welfare. National Guidelines for Diagnosis and Treatment of Malaria. Tanzania, Dar es Salaam, 2006.
Medicines for Malaria Venture & WHO. Methods and techniques for clinical trials on antimalarial drug efficacy : genotyping to identify parasite populations : informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization, 29–31 May 2007, Amsterdam, The Netherlands. Geneva, World Health Organization, 2008. https://iris.who.int/handle/10665/43824 .
WHO Informal consultation on methodology to distinguish reinfection from recrudescence in high malaria transmission areas: report of a virtual meeting, 17–18 May 2021. Geneva, World Health Organization, 2021. https://iris.who.int/handle/10665/348385 .
Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S. Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malar J. 2007;6:146.
doi: 10.1186/1475-2875-6-146
pubmed: 17996121
pmcid: 2194692
Mandara CI, Francis F, Chiduo MG, Ngasala B, Mandike R, Mkude S, et al. High cure rates and tolerability of artesunate–amodiaquine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma. Tanzania Malar J. 2019;18:99.
doi: 10.1186/s12936-019-2740-z
pubmed: 30909922
Hastings IM, Felger I. WHO antimalarial trial guidelines: good science, bad news? Trends Parasitol. 2022;38:933–41.
doi: 10.1016/j.pt.2022.08.005
pubmed: 36068129
Shayo A, Buza J, Ishengoma DS. Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania. Malar J. 2015;14:135.
doi: 10.1186/s12936-015-0649-8
pubmed: 25889242
pmcid: 4415202
WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. Geneva, World Health Organization, 2018. https://iris.who.int/handle/10665/274362 .
WWARN. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. BMC Med. 2019;17:1.
Bwire GM, Ngasala B, Mikomangwa WP, Kilonzi M, Kamuhabwa AA. Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. Sci Rep. 2020;10:3500.
doi: 10.1038/s41598-020-60549-7
pubmed: 32103124
pmcid: 7044163
Mhamilawa LE, Aydin-Schmidt B, Mmbando BP, Ngasala B, Morris U. Detection of Plasmodium falciparum by light microscopy, loop-mediated isothermal amplification, and polymerase chain reaction on day 3 after initiation of artemether-lumefantrine treatment for uncomplicated malaria in Bagamoyo District, Tanzania: a comparative trial. Am J Trop Med Hyg. 2019;101:1144–7.
doi: 10.4269/ajtmh.19-0298
pubmed: 31549618
pmcid: 6838587
Ehrlich HY, Bei AK, Weinberger DM, Warren JL, Parikh S. Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. Proc Natl Acad Sci USA. 2021;118: e2100685118.
doi: 10.1073/pnas.2100685118
pubmed: 34261791
pmcid: 8307356
Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833–43.
doi: 10.4269/ajtmh.14-0031
pubmed: 25048375
pmcid: 4183414
Salvador C, Rafael B, Matsinhe F, Candrinho B, Muthemba R, De Carvalho E, et al. Efficacy and safety of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, 2015. Acta Trop. 2017;171:146–50.
doi: 10.1016/j.actatropica.2017.03.032
pubmed: 28373036